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Introduction
Platelets play an important role in hemostasis and vascular 
integrity. They have a unique mechanism of derivation as frag-
ments from the cytoplasm of bone marrow megakaryocytes. 
Abnormalities in platelet number, either increase (thrombo-
cytosis) or decrease (thrombocytopenia), accompany diverse 
pathologic conditions and may aid in their diagnosis [1]. Can-
cer is a pathology that is often associated with thrombocyto-
sis. This relates to the cytokine context of several malignancies 
that stimulates thrombopoiesis. Possibly due to this fact of 
association with a particular cytokine setting, thrombocytosis 
has been found to be an adverse prognostic factor in many 
common malignancies.
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Objective
Thrombocytosis is an adverse prognostic factor in many types of cancer. We investigated if pre-treatment increased 
platelet counts provide prognostic information specifically in patients with stage III and IV serous ovarian cancer 
which is the most common clinical presentation of ovarian cancer.
Methods
Platelet number on diagnosis of stage III and IV serous ovarian adenocarcinoma was evaluated in 91 patients for 
whom there were complete follow-up data on progression and survival. Survival and progression free survival of 
patients with normal platelet counts (150–350 ×109/L) was compared with that of patients with thrombocytosis (>350 
×109/L) by X2 and logrank tests.
Results
The median age of the patients was 66 years-old. From the 91 patients, 52 (57.1%) had normal platelet counts (median, 
273 ×109/L; range, 153–350) at diagnosis of their disease and 39 patients (42.9%) had thrombocytosis (median, 463 
×109/L; range, 354–631). In the group of patients with normal platelet counts, 24 of the 52 patients had died with a 
median survival of 43 months (range, 3–100). In the group of patients with thrombocytosis, 24 of the 39 patients had 
died with a median survival of 23 months (range, 4–79). In the entire group of 91 patients there was a statistically 
significant difference of the overall survival and progression-free survival between the two groups (logrank test 
P=0.02 and P=0.007, respectively).
Conclusion
In this retrospective analysis of stage III and IV ovarian cancer patients, thrombocytosis at the time of diagnosis had 
prognostic value regarding overall survival and progression-free survival.
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Ovarian cancer is one of the most common female ma-
lignancies. It is asymptomatic in initial stages and as a result 
it is diagnosed in many patients after intra-abdominal dis-
semination or even after becoming metastatic in distant sites. 
Ovarian carcinoma presents as localized or regional disease in 
about 30% of cases and as extensive disease in the rest [2]. 
Histologically ovarian adenocarcinomas are divided to several 
sub-types such as serous, endometrioid, mucinous and clear 
cell, in decreasing order of frequency [3]. Ovarian cancer is 
treated with debulking surgery and often with adjuvant che-
motherapy to prolong the time to progression or decrease 
the risk of recurrence [4]. Stage is the main prognostic fac-
tor and determinant for the administration of chemotherapy 
after ovarian cancer surgery [5]. Histologic subtypes possess 
also prognostic information with some being more aggressive 
than others [6,7] but additional markers are needed to further 
promote prognostication of ovarian cancer in the individual 
patient inside each histologic group. In patients with epithe-
lial ovarian cancer of all stages and histologic sub-types, pre-
treatment thrombocytosis was an independent prognostic 
factor for overall survival (OS) and progression-free survival 
[8]. We investigated if pre-treatment thrombocytosis provide 
prognostic information specifically in patients with advanced 
stage serous ovarian cancer who represent the most frequent 
setting of presentation.
Materials and methods 
Platelet number at diagnosis of stage III and IV serous ovarian 
adenocarcinoma was evaluated in 91 patients treated in our 
hospital and for whom there were complete follow-up data 
on progression free (PFS) and OS. Case records of women 
with ovarian cancer treated over the last 12 years were ret-
rospectively reviewed. PFS and OS of patients with normal 
platelet counts (150–350 ×109/L) were compared with that of 
patients with thrombocytosis (>350 ×109/L) by X2 and logrank 
tests. Patients with other histologic types of ovarian cancer or 
earlier stages of disease were excluded.
Follow-up was considered complete if a patient was fol-
lowed till her death or was seen within the last 6 months from 
data collection. Data on patients’ age, menopause status, 
histologic characteristics of tumor, stage, site(s) of metastases, 
tumor marker CA-125 at diagnosis and completeness of sur-
gery (defined as maximal residual disease of less than 1 cm) 
were recorded. Platelet number on diagnosis of ovarian cancer 
(before the start of any therapy) was also recorded. All pa-
tients had received standard peri-operative chemotherapy with 
carboplatin and paclitaxel. OS was defined as the interval from 
the date of diagnosis to death. PFS was defined as the interval 
from the date of diagnosis to disease progression or death, 
whichever happened first. Survival plots of patients with nor-
mal platelet counts and thrombocytosis were constructed us-
ing the Kaplan-Meier method and were compared using the 
logrank test [9]. The X2 test was used to evaluate differences 
in clinical and biologic characteristics in the two groups [10]. 
A Cox regression proportional hazard multivariate analysis was 
performed to identify statistically significant factors associated 
with overall and PFS survival. All P-values were considered to 
be significant at the level of P<0.05. Statistical calculations 
were performed with on-line tools available from the Technical 
University of Denmark (https://statcom.dk/K-M_plot.php) and 
a non-commercial site (http://www.statpages.org).
Results 
The median age of the patients was 66 years old. From the 
91 patients, 52 (57.1 %) had normal platelet counts (median, 
273 ×109/L; range, 153–350) at diagnosis of their disease and 
39 patients (42.9 %) had thrombocytosis (median, 463 ×109/
L; range, 354–631) (Table 1). The median age of the patients 
with normal counts was 65 years old (range, 27–87) and of 
those with thrombocytosis was 70 years old (range, 41–90). In 
the normal platelet group 50% of patients were older than 65 
years-old while in the thrombocytosis group 59% were older 
than 65 years old (X2 test P=0.39). Stage was III in 61.5% and 
IV in 38.5% of patients with normal platelets while 71.8% of 
patients with thrombocytosis had stage III disease and 28.2% 
had stage IV disease (X2 test P=0.3). Surgery was complete in 
49% and 69.2% of normal platelet and thrombocytosis pa-
tients respectively (X2 test P=0.052). In the group of patients 
with normal platelet counts, 24 of the 52 patients (46.2%) 
had died with a median survival of 43 months (range, 3–100) 
and 28 patients were alive at last follow-up with a median 
follow-up of 32.5 months (range, 1–140). In the group of pa-
tients with thrombocytosis, 24 of the 39 patients (61.5%) had 
died with a median survival of 23 months (range, 4–79) and 
15 patients were alive at last follow-up with a median follow-
up of 20 months (range, 4–69). Among the 48 patients (24 
patients in each group) who had died, the 3 year survival of 
patients with normal platelet counts was 54.2% and of pa-
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tients with thrombocytosis was 33.3%. 
In the entire group of 91 patients there was a statistically 
significant difference of the OS between the two groups (lo-
grank test P=0.02) (Fig. 1). In the multivariate Cox regression 
analysis, stage (IV vs. III) and thrombocytosis were statistically 
significantly associated with reduced OS while increasing age 
(as a continuous variable), menopausal status, tumor marker 
CA-125 at diagnosis and completeness of surgery were not 
(Table 2). A CA-125 cut-off of 1,000 IU/L that, in some cen-
ters, influences the decision of proceeding with neo-adjuvant 
chemotherapy was used in the model. 
PFS was similarly in favor of the normal platelets group 
(logrank test P=0.007) (Fig. 2). In the multivariate Cox regres-
sion analysis, stage IV, incomplete surgery and thrombocytosis 
Table 2. Multivariate Cox regression analysis of parameters possibly related to overall survival of ovarian cancer patients CA-125 cut-off 
point for this analysis was 1000 IU/L
Variable Hazard ratio
95% confidence interval
P-value
Lower limit Upper limit
Age 1.01 0.98 1.04 0.31
Menopause status 2.61 0.65 10.4 0.17
Stage 2.83 1.41 5.70 0.0034
CA-125a) 0.87 0.45 1.68 0.69
Completeness of surgery 1.54 0.73 3.24 0.24
Thrombocytosis 2.07 1.08 3.97 0.02
a)Cut-off point for this analysis was 1,000 IU/L.
Table 1. Characteristics and outcome of patients in the series
Alla) Normal platelets Thrombocytosis P-value
Patients 91 (100) 52 (57.1) 39 (42.9)
Age (yr) 66 (27–90) 65 (27–87) 70 (41–90) 0.39
Stage
Ⅲ 60 (65.9) 32 (61.5) 28 (71.8) 0.3
Ⅳ 31 (34.1) 20 (38.5) 11 (28.2)
Completeness of surgery number (%) 52 (51.7) 25 (49) 27 (69.2) 0.05
CA-125 ＞1,000 36 (42.4) 20 (40.8) 16 (44.4) 0.11
Overall survival  in months 28.5 (3–100) 43 (3–100) 23 (4–79)
Values are presented as n (%) or median (range).   
a)All includes the totality of patients. 
Fig. 1. Kaplan-Meier overall survival (OS) curves in months from diag-
nosis of ovarian cancer in patients with normal platelet counts (150–350 
×109/L) versus patients with thrombocytosis. Logrank test P=0.02.
Fig. 2. Kaplan-Meier progression free survival curves in months from di-
agnosis of ovarian cancer in patients with normal platelet counts (15–350 
×109/L) versus patients with thrombocytosis. Logrank test P=0.0007.
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were statistically significantly associated with reduced PFS 
while increasing age, menopausal status and tumor marker 
CA-125 at diagnosis were not (Table 3).
Discussion
Cancer is together with infection, trauma or surgery and iron 
deficiency a cause of secondary thrombocytosis. In one study, 
occult cancer was present in 40% of patients with thrombo-
cytosis of more than 400 ×109/L when other common condi-
tions were excluded [11]. In addition, emerging data reveal 
that thrombocytosis is a reverse prognostic factor in a wide 
range of carcinomas such as localized [12] and metastatic 
breast cancer [13], gastrointestinal cancers [14-16] and geni-
tourinary cancers [17,18].
Several studies have dealt with the significance of thrombo-
cytosis in epithelial ovarian cancer with conflicting results. In a 
study of 619 patients with ovarian carcinoma of all stages and 
various histologic types, thrombocytosis (defined as a platelet 
count of more than 450 ×109/L) was associated with more ad-
vanced stage and higher preoperative CA-125 [8]. In addition 
the median OS in patients with thrombocytosis was 2.62 years 
while in the group with normal platelets it was 4.65 years 
(P<0.001). In a multivariate analysis thrombocytosis, more 
advanced stage (III or IV), high grade and suboptimal cytore-
duction emerged as statistically significant. In another study 
in ovarian cancer across stages and histologic types, thrombo-
cytosis (defined as platelets more than 400 ×109/L) was also 
associated with advanced stage and grade and reduced OS 
[19]. This was in contrast to a study of 136 patients also of all 
stages and histologies that showed that, although thrombo-
cytosis was associated with reduced overall and disease-free 
survival in univariate analysis, this association was no longer 
present in multivariate analysis [20]. Still another study of 183 
advanced epithelial ovarian cancer patients of all histologies 
associated thrombocytosis (defined as platelets more than 400 
×109/L) with both decreased overall and disease-free survival 
[21]. In a more recent analysis of 587 patients (various histolo-
gies) focusing on peri-operative factors, thrombocytosis (plate-
lets more than 450 ×109/L) was associated with decreased OS 
only in stage I/ II but not in stage III/ IV disease [22]. 
In order to clarify some of these conflicting results we under-
took the current investigation which represents the first series 
including only advanced stage patients with serous histology. 
In this retrospective study we show that thrombocytosis is as-
sociated with decreased OS and PFS in 91 patients with this 
specific stage and histology representing the most common 
clinical presentation of ovarian cancer. The two groups with 
normal platelets and thrombocytosis were similar regarding 
the age of patients and the distribution of stage III and IV. The 
thrombocytosis group had a border line statistically significant 
higher percentage of patients with complete surgery. In the 
multivariate analysis, stage IV disease and thrombocytosis 
were associated with decreased OS while these two factors 
together with incomplete surgery were associated with de-
creased progression-free survival. Completeness of surgery 
was not associated with OS possibly because of effectiveness 
of multiple lines of chemotherapy in controlling the disease.
Concerning the pathogenesis of thrombocytosis, the above 
mentioned investigation of 619 patients has shed some light. 
Thrombocytosis was significantly correlated with plasma lev-
els of interleukin (IL)-6 [8]. In mouse models bearing human 
ovarian cancer, human IL-6 stimulates hepatocytes through 
the IL-6 receptor to trigger thrombopoietin production. Thus a 
proposed model stipulates that ovarian cancer tumor cells pro-
duce IL-6 which stimulates hepatic thrombopoietin production. 
Ovarian cancer patients have higher serum thrombopoietin 
Table 3. Multivariate Cox regression analysis of parameters possibly related to progression free survival of ovarian cancer patients
Variable Hazard ratio
95% confidence interval
P-value
Lower limit Upper limit
Age 0.99 0.96 1.02 0.69
Menopause status 1.05 0.40 2.77 0.91
Stage 2.53 1.37 4.66 0.002
CA-125 1.12 0.67 1.85 0.65
Completeness of surgery 2.01 1.07 3.76 0.02
Thrombocytosis 2.21 1.28 3.81 0.004
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levels than patients with benign ovarian masses and these lev-
els fall after surgical rejection [23]. Thrombopoietin increases 
thrombopoiesis through stimulation of megakaryocyte pro-
genitors in the bone marrow [8]. In other cancers IL-6 may also 
play a similar role in favoring thrombocytosis and increased se-
rum levels or tumor positivity by immuno-histochemistry have 
been detected in a variety of cancer types [24-26].
The mechanistic basis of platelets contribution to carcino-
genesis is a subject of investigation [27]. Circulating tumor 
cells may use platelets as a protective shield from the attack 
of the immune system and as facilitators for attachment to 
endothelial cells at metastatic sites. Platelets have also roles 
in carcinogenesis directly related to their normal function in 
promotion of vascular integrity [28]. Newly formed tumor 
vasculature lacks the normal architecture and robustness 
of resident vasculature and platelets have been shown to 
be indispensable for preventing hemorrhage in tumor beds 
[29]. Both alpha and dense granules of platelets carry bioac-
tive molecules and growth factors [30,31]. These include 
vascular endothelial growth factor (VEGF), epidermal growth 
factor, platelet derived growth factor, hepatocyte growth 
factor, insulin-like growth factor, transforming growth factor 
β (TGFβ), IL-1β, IL-8, CXC motif containing ligand 12, sphin-
gosine 1-phosphate and lysophosphatidic acid [30,32]. Each 
of these molecules may actively facilitate metastatic progres-
sion. An example is platelet-derived TGFβ which promotes an 
epithelial to mesenchymal transition (EMT) program in cancer 
cells through transcription factors Smad and nuclear factor-κB 
signaling [33]. EMT constitutes a program endowing epithelial 
cells with a mesenchymal phenotype that promotes mobility 
and metastasis while protecting them from anoikis (Apoptosis 
due to lack of adhesion) [34]. There exist quantitative differ-
ences in platelet cargo of bioactive factors in malignancy and 
platelets from patients with cancer have a higher VEGF level 
than platelets from individuals without cancer [35]. As a result, 
both increased platelet counts and bioactive factor content 
may contribute to increased VEGF concentrations in the tumor 
and metastases sites environment where they are activated. 
In conclusion, this retrospective analysis of a series of ad-
vanced serous ovarian cancer patients shows that thrombocy-
tosis (defined in this paper as platelets more than 350 ×109/
L) at the time of diagnosis has prognostic value regarding OS 
and PFS. The presence of thrombocytosis is independent in 
multivariate analysis of other known prognostic characteristics 
and thus has value beyond these characteristics. An important 
question for future investigation is whether thrombocytosis 
can serve as a predictive marker of specific treatments, for 
example of anti-VEGF therapies. Indeed a recent study in 
metastatic renal cell carcinoma has shown that patients with 
thrombocytosis had a higher risk to present a primary refrac-
toriness to anti-VEGF treatments (odds ratio, 1.7; P=0.0068) 
than patients with normal platelets [36]. It remains to be seen 
if thrombocytosis could be a predictive factor for anti-VEGF 
therapies in other cancers and in ovarian cancer in particular 
where the anti-VEGF monoclonal antibody bevacizumab has 
been recently approved for clinical use [37].
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